Literature DB >> 15917119

A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies.

Astrid Geldmacher1, Dace Skrastina, Galina Borisova, Ivars Petrovskis, Detlev H Krüger, Paul Pumpens, Rainer Ulrich.   

Abstract

Hepatitis B virus (HBV) core particles carrying the amino-terminal 120 amino acids (aa) of the nucleocapsid (N) protein of the hantaviruses Dobrava, Hantaan or Puumala have been demonstrated to be highly immunogenic in mice when complexed with adjuvants. Here we demonstrate that even without adjuvant, these chimeric particles induced high-titered, and strongly cross-reactive N-specific antibody responses in BALB/c and C57BL/6 mice. The induced N-specific antibodies represented all IgG subclasses. Pre-existing core-specific antibodies did not abrogate the induction of an N-specific immune response by a hantavirus N insert presented on core particles. Therefore, chimeric core particles should represent promising vaccine candidates even for anti-core positive humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917119     DOI: 10.1016/j.vaccine.2005.02.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Hepatitis B virus morphogenesis.

Authors:  Volker Bruss
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 2.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

3.  A new Puumala hantavirus subtype in rodents associated with an outbreak of Nephropathia epidemica in South-East Germany in 2004.

Authors:  S Essbauer; J Schmidt; F J Conraths; R Friedrich; J Koch; W Hautmann; M Pfeffer; R Wölfel; J Finke; G Dobler; R Ulrich
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

4.  NMR structure of the N-terminal coiled coil domain of the Andes hantavirus nucleocapsid protein.

Authors:  Yu Wang; Daniel M Boudreaux; D Fernando Estrada; Chet W Egan; Stephen C St Jeor; Roberto N De Guzman
Journal:  J Biol Chem       Date:  2008-08-07       Impact factor: 5.157

5.  SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure.

Authors:  Andreas Walker; Claudia Skamel; Michael Nassal
Journal:  Sci Rep       Date:  2011-06-14       Impact factor: 4.379

Review 6.  Progress on the Prevention and Treatment of Hantavirus Disease.

Authors:  Rebecca L Brocato; Jay W Hooper
Journal:  Viruses       Date:  2019-07-04       Impact factor: 5.048

7.  Evaluation of Trichodysplasia Spinulosa-Associated Polyomavirus Capsid Protein as a New Carrier for Construction of Chimeric Virus-Like Particles Harboring Foreign Epitopes.

Authors:  Alma Gedvilaite; Indre Kucinskaite-Kodze; Rita Lasickiene; Albertas Timinskas; Ausra Vaitiekaite; Danguole Ziogiene; Aurelija Zvirbliene
Journal:  Viruses       Date:  2015-07-29       Impact factor: 5.048

Review 8.  Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses.

Authors:  Joseph W Golden; Christopher D Hammerbeck; Eric M Mucker; Rebecca L Brocato
Journal:  Biomed Res Int       Date:  2015-07-21       Impact factor: 3.411

9.  Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Authors:  Milena Lange; Melanie Fiedler; Dorothea Bankwitz; William Osburn; Sergei Viazov; Olena Brovko; Abdel-Rahman Zekri; Yury Khudyakov; Michael Nassal; Paul Pumpens; Thomas Pietschmann; Jörg Timm; Michael Roggendorf; Andreas Walker
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

Review 10.  Nanoparticle Vaccines Against Infectious Diseases.

Authors:  Rashmirekha Pati; Maxim Shevtsov; Avinash Sonawane
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.